Rosuvastatin 40 mg efficacy and safety
Pro Research Analysisby 
Searched over 200M research papers
Efficacy of Rosuvastatin 40 mg in High-Risk Patients
Rosuvastatin 40 mg is highly effective in lowering low-density lipoprotein cholesterol (LDL-C) and other atherogenic lipids in patients at high or very high cardiovascular risk. Studies in patients with acute coronary syndrome (ACS) and familial hypercholesterolemia (FH) show that rosuvastatin 40 mg can reduce LDL-C by approximately 45-55%, total cholesterol, and triglycerides, while also improving ratios such as LDL-C/HDL-C and reducing inflammatory markers like high-sensitivity C-reactive protein (hsCRP) 1234+1 MORE. In real-world and clinical trial settings, more than half of high-risk patients achieved LDL-C targets below 70 mg/dL after 12 weeks of therapy . In patients with FH, LDL-C was reduced by 50% and apolipoprotein B by 45% over 16 weeks, with additional reductions in triglycerides and hsCRP .
Comparative Efficacy: Rosuvastatin 40 mg vs. Other Statins
When compared to high-dose atorvastatin (80 mg), rosuvastatin 40 mg demonstrated superior or comparable efficacy in reducing LDL-C and triglycerides, and was more effective in increasing HDL-C 34. In head-to-head studies, rosuvastatin 40 mg enabled a greater proportion of patients to reach LDL-C goals than simvastatin 80 mg, and was at least as effective as atorvastatin 80 mg in improving lipid profiles and inflammatory markers 348. In patients with type 2 diabetes and previous ACS, high-dose rosuvastatin (20 mg) and atorvastatin (40 mg) were similarly effective, with no significant differences in achieving LDL-C reduction targets .
Safety Profile of Rosuvastatin 40 mg
Rosuvastatin 40 mg is generally well tolerated, with a safety profile similar to other statins at high doses. Across large clinical trial programs and real-world studies, the incidence of adverse events, including muscle symptoms and liver enzyme elevations, was low and comparable to other statins 1234+4 MORE. Myopathy and rhabdomyolysis rates at 40 mg were similar to other statins, and clinically significant elevations in liver enzymes or creatine kinase were rare 67. In long-term studies, rosuvastatin 40 mg did not cause significant renal dysfunction; transient proteinuria was observed in a small proportion of patients but was not associated with kidney damage 78. In patients with comorbidities such as hypertension and chronic obstructive pulmonary disease, rosuvastatin 40 mg was safe and did not cause adverse reactions over 12 months of use .
Tolerability and Real-World Use
Real-world data confirm the effectiveness and safety of rosuvastatin 40 mg for both primary and secondary prevention of cardiovascular events, with adverse events reported in less than 1% of patients . The drug is well tolerated even in populations with multiple comorbidities, and side effects such as myalgia or liver enzyme elevations are infrequent and generally mild 1247+2 MORE.
Conclusion
Rosuvastatin 40 mg is a potent and effective statin for lowering LDL-C and other atherogenic lipids in high-risk patients, including those with ACS, FH, and multiple comorbidities. Its safety profile is comparable to other high-dose statins, with a low incidence of serious adverse effects. Rosuvastatin 40 mg is a reliable option for intensive lipid-lowering therapy in patients requiring aggressive cardiovascular risk reduction 1234+5 MORE.
Sources and full results
Most relevant research papers on this topic
Efficacy and safety of Mertenil (rosuvastatin) 40 mg in patients with familial hypercholesterolemia
Mertenil (rosuvastatin) 40 mg is an effective and safe treatment for heterozygous familial hypercholesterolemia, reducing LDL-c and ApoB-100 levels without causing side-effects.
DOI
Short Term Comparison Between Safety and Efficacy of Rosuvastatin 40 mg and Atorvastatin 80 mg in Patients with Acute Coronary Syndrome
Rosuvastatin 40 mg/day is safer and more effective than atorvastatin 80 mg/day in reducing lipid parameters and inflammatory biomarkers in patients with acute coronary syndrome.
Efficacy and Safety of Atorvastatin 40 mg versus Rosuvastatin 20 mg in Patients with Type 2 Diabetes Mellitus and Previous Acute Coronary Syndrome: A Randomized Clinical Trial
High-dose atorvastatin (40 mg) and rosuvastatin (20 mg) are comparable in efficacy and safety for patients with type 2 diabetes and previous acute coronary syndrome history in Egypt.
Safety of Rosuvastatin: Update on 16,876 Rosuvastatin-Treated Patients in a Multinational Clinical Trial Program
Rosuvastatin is well-tolerated and has a similar safety profile to other statins, with rare adverse events and no deaths attributed to the drug.
Lipid-lowering therapy for patients with arterial hypertension and concomitant chronic obstructive pulmonary disease in a south American cohort.
Rosuvastatin at a dose of 40 mg effectively reduces total cholesterol, LDL, and triglycerides, improves endothelial function, and is safe for patients with dyslipidemia, hypertension, and COPD.
DOI